Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical Inc. has announced new data from University College London demonstrating the efficacy of its Steriwave photodisinfection technology against the Mucor fungus, a serious threat to immunocompromised patients. The findings, presented at the 19th World Congress of the International Photodynamic Association, highlight Steriwave’s potential to significantly reduce healthcare-associated infections by effectively decolonizing nasal passages of fungal pathogens, offering a promising new approach to infection prevention in hospital settings.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with its nasal photodisinfection system, Steriwave, approved in several countries and undergoing clinical trials in the US.
Average Trading Volume: 140,110
Technical Sentiment Signal: Sell
Current Market Cap: £39.89M
Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.